Axogen, Inc. (AXGN)

Market Cap	842.09M
Revenue (ttm)	187.34M
Net Income (ttm)	-9.96M
Shares Out	44.34M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	940,279
Open	18.18
Previous Close	18.15
Day's Range	18.15 - 19.41
52-Week Range	5.55 - 21.00
Beta	1.02
Analysts	Strong Buy
Price Target	24.17 (+27.28%)
Earnings Date	May 1, 2025

About AXGN

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Michael Dale
• Employees: 452
• Stock Exchange: NASDAQ
• Ticker Symbol: AXGN
• Website: https://www.axogeninc.com

Financial Performance

In 2024, Axogen's revenue was $187.34 million, an increase of 17.81% compared to the previous year's $159.01 million. Losses were -$9.96 million, -54.12% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price forecast is $24.17, which is an increase of 27.28% from the latest price.

Price Target

$24.17

(27.28% upside)

Analyst Consensus: Strong Buy